Colchicine for 12 months.
ApprovedSmall molecule
Colchicine for 12 months. is one of 27 small molecule programs targeting Coronary Atherosclerosis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Coronary Atherosclerosis
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Colcrys
Alnylam PharmaceuticalsApproved
Precose
BayerApproved
Actos
TakedaApproved
Mounjaro
Eli LillyApproved
Benicar
CCosette Pharmaceuticals, Inc.
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Colchicine for 12 months.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SShenyang Northern Hospital